Elevated LGI1‐IgG CSF index predicts worse neurological outcome

To determine whether CSF leucine‐rich glioma‐inactivated 1(LGI1)‐IgG titer, index or IgG subclass has prognostic significance, we tested serum and CSF specimens collected concomitantly from 39 seropositive patients. LGI1‐IgG index was elevated (>1) in 21 patients (54%), suggesting intrathecal syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadoth, Avi, Zekeridou, Anastasia, Klein, Christopher J., Thoreson, Colton J., Majed, Masoud, Dubey, Divyanshu, Flanagan, Eoin P., McKeon, Andrew, Jenkins, Sarah M., Lennon, Vanda A., Pittock, Sean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945965/
https://www.ncbi.nlm.nih.gov/pubmed/29761127
http://dx.doi.org/10.1002/acn3.561
Descripción
Sumario:To determine whether CSF leucine‐rich glioma‐inactivated 1(LGI1)‐IgG titer, index or IgG subclass has prognostic significance, we tested serum and CSF specimens collected concomitantly from 39 seropositive patients. LGI1‐IgG index was elevated (>1) in 21 patients (54%), suggesting intrathecal synthesis. Patients with worse outcome at last follow‐up (modified Rankin Scale >2) had significantly higher index (median 6.57 vs. 0.5, P = 0.048) compared to those with better outcome. Higher CSF LGI1‐IgG4 subclass‐specific titer and index correlated with worse outcome (P < 0.005 for both). These data suggest that evidence of intrathecal LGI1‐IgG synthesis may correlate with neuronal injury and warrant consideration of aggressive immunotherapy.

Ejemplares similares